Westerik JA, Carter V, Chrystyn H, Burden A, Thompson SL, Ryan D, Gruffydd-Jones K5, Haughney J, Roche N, Lavorini F, Papi A, Infantino A,Roman-Rodriguez M11, Bosnic-Anticevich S, Lisspers K, Ställberg B, Henrichsen SH, van der Molen T, Hutton...
Read moreChanges in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational
Gruffydd-Jones K, Brusselle G, Jones R, Miravitlles M, Baldwin M, Stewart R, Rigazio A, Davis E, Keininger DL, Price D NPJ Prim Care Respir Med 2016; 26: 16002. [Full Text]
Read moreCost-effectiveness of asthma step-up therapy as an increased dose of extrafine-particle inhaled corticosteroid or add-on long-acting beta2-agonist
Roche N, ColiceG, Israel E, Martin RJ, Dorinsky PM, Postma DS, Guilbert TW, Grigg J, van Aalderen WMC, Barion F, Hillyer EV, Thomas V, Burden A, McQueen RB, Price DB Pulm Ther 2016; 2: 73-89. [Full Text]
Read moreAdd-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
Price DB, Colice G , Israel E , Roche N , Postma DS , Guilbert TW , van Aalderen WMC, Grigg J, Hillyer EV , Thomas V, Martin RJ ERJ Open Res 2016; 2(2). [Full Text]
Read moreComorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry
Sweeney J, Patterson CC, Menzies-Gow A, Niven RM, Mansur AH, Bucknall C, Chaudhuri R, Price D, Brightling CE, Heaney LG; on behalf of the British Thoracic Society Difficult Asthma Network Thorax 2016; 71(4): 339-46. [PubMed][Full Text]
Read moreMulti-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets
Jones RC, Price D, Chavannes NH, Lee AJ, Hyland ME, Ställberg B, Lisspers K, Sundh J, van der Molen T, Tsiligianni I; UNLOCK Group of the IPCRG NPJ Prim Care Respir Med 2016; 26: 16010. [PubMed][Full Text]
Read moreAre pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG
Lisspers K, Teixeira P, Blom C, Kocks J, Ställberg B, Price D, Chavannes N NPJ Prim Care Respir Med 2016; 26: 16016. [PubMed][Full Text]
Read moreImpacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database
Lee H, Rhee CK, Lee BJ, Choi DC, Kim JA, Kim SH, Jeong Y, Kim TH, Chon GR, Jung KS, Lee SH, Price D, Yoo KH, Park HY Int J Chron Obstruct Pulmon Dis 2016; 11(1): 775–83. [PubMed][Full Text]
Read moreUK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study.
Price DB, Scadding G, Bachert C, Saleh H, Nasser S, Carter V, Ziegenweidt JV, Durieux AMS, Ryan D NPJ Prim Care Respir Med 2016. [PubMed][Full Text]
Read moreUnderuse of β-blockers in heart failure and chronic obstructive pulmonary disease
Lipworth B, Skinner D, Devereux G, Thomas V, Ling JZJ, Martin J, Carter V, Price DB Heart 2016. [Full Text]
Read moreLong-acting β-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
Turner S, Richardson K, Murray C, Thomas M, Hillyer EV, Burden A, Price DB; Respiratory Effectiveness Group J Allergy Clin Immunol Pract 2016. [PubMed][Full Text]
Read moreComparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label
Lead Author: Henry Chrystyn et al Published: 13/05/2016 Journal: BMC Pulmonary Medicine. 2016 16:12.
Read more